Helsinn And BridgeBio Ink Infigratinib Cancer Pact
Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology
Executive Summary
Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.
You may also be interested in...
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
Russia’s RDIF and Sberbank Launch $100m Start-Up Fund
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.
Roxadustat CKD Doubts Fanned By FibroGen Data Blunder
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.